Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novel Saltwater Treatment Device

Published: Monday, May 27, 2013
Last Updated: Monday, May 27, 2013
Bookmark and Share
Cambridge Consultants develops innovative nebulizer to treat cystic fibrosis.

Observing surfers with cystic fibrosis (CF) led scientists to discover that the inhaled mist of seawater has a therapeutic effect on the lung problems associated with the disease.

Now the findings have been used by pharmaceutical company Parion Sciences and product development firm Cambridge Consultants in a revolutionary new aerosol delivery system.

It enables CF sufferers to get the benefits of saltwater treatment in their own homes overnight while they sleep.

“We have seen evidence that routine exposure to salt water reduces the number of lung infections in CF patients and leads to fewer hospital admissions - but the challenge was to develop an optimal delivery system,” said Dr Richard Boucher, co-founder and chairman of Parion.

Dr Boucher continued, “We enlisted Cambridge Consultants to design the system, given its track record of creating world firsts in drug delivery device development - and the results have exceeded our expectations.”

CF is a chronic disease that affects the lungs and digestive system of more than 70,000 adults and children worldwide. Studies have shown that the inhalation of a hypertonic saltwater solution improves the condition of sufferers by rehydrating the layer of mucus film that lines their lungs.

Cambridge Consultants conducted human-factor studies and applied its expertise in fluid dynamics to develop a system that could deliver an aerosol mist through the nose continuously for eight hours.

“We immediately recognized the potential of this project to transform the lives of CF patients,” said Matthew Allen, programme director at Cambridge Consultants. “The challenge was to build an aerosol nebulizer system that could be comfortably used by patients overnight - with the saline mist travelling down a long cannula to the sleeping patient without forming the large droplets that often occur in a standard nebulizer system. The size of the saline droplets is crucial to the success of the treatment as they need to be small enough to penetrate deep into the lungs.”

The tPAD (trans-nasal pulmonary aerosol delivery) device has been assessed in a clinical trial - and so greatly exceeded its predicted performance that additional devices have now been requested to support further clinical trials.

The aim is to provide an easy and effective treatment system for CF patients that is suitable even for young children and allows the disease to be treated at the earliest possible stages.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!